Inhibikase

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Inhibikase and other ETFs, options, and stocks.

About IKT

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases.

CEO

Mark T. Iwicki

CEOMark T. Iwicki

Employees

Employees16

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

2008

Founded2008

Employees

Employees16

IKT Key Statistics

Market cap

198.27M

Market cap198.27M

Price-Earnings ratio

-2.93

Price-Earnings ratio-2.93

Dividend yield

—

Dividend yield—

Average volume

527.90K

Average volume527.90K

High today

$1.65

High today$1.65

Low today

$1.61

Low today$1.61

Open price

$1.65

Open price$1.65

Volume

58.06K

Volume58.06K

52 Week high

$3.32

52 Week high$3.32

52 Week low

$1.33

52 Week low$1.33

Stock Snapshot

Inhibikase(IKT) stock is priced at $1.64, giving the company a market capitalization of 198.27M. It carries a P/E multiple of -2.93.

On 2026-01-20, Inhibikase(IKT) stock moved within a range of $1.61 to $1.65. With shares now at $1.64, the stock is trading +1.5% above its intraday low and -0.9% below the session's peak.

Trading activity shows a volume of 58.06K, compared to an average daily volume of 527.9K.

Over the past 52 weeks, Inhibikase(IKT) stock has traded between a high of $3.32 and a low of $1.33.

Analyst ratings

100%

of 6 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own IKT. This list is generated using Robinhood data, and it’s not a recommendation.